| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 760 3 |
| Ultima descărcare din IBN: 2019-06-11 13:08 |
| Căutarea după subiecte similare conform CZU |
| 616.74-002-021.3 (1) |
| Patologia organelor de locomoţie. Sistemul osos şi locomotor (469) |
 SM ISO690:2012LOGHIN-OPREA, Natalia, VETRILĂ, Snejana, MAZUR-NICORICI, Lucia, MAZUR, Minodora. Consecinţele timpurii ale miopatiilor inflamatorii idiopatice. In: Sănătate Publică, Economie şi Management în Medicină , 2017, nr. 3(73), pp. 143-145. ISSN 1729-8687. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Sănătate Publică, Economie şi Management în Medicină | ||||||
| Numărul 3(73) / 2017 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
| CZU: 616.74-002-021.3 | ||||||
| Pag. 143-145 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Idiopathic inflammatory myopathies (IIM) are a group of rare diseases characterized by asthenia of skeletal muscles. Early approach to disease leads to a favorable evolution of the disease and less outcomes. The aim of this study is to assess the short-term outcomes in patients with IIM. We conducted a transversal study enrolling 12 patients (7 women, 5 men) with IIM, the mean age was 54.1±12.1 (30–67) years and the follow–up period was 16±9.4, (7-25) months. Patients were assessed by aplying specific questionnaires and modern, validated clinical tools.We found in all patients muscle damage manifested by muscular dysfunction – 11 (91.7%) patients and atrophy in one (8,3%) patient, confirmed by moderate muscle strengh, which implies disability – 10 (83.3%) patients. Gastrointestinal damage was manifested by dysphagia in 3 (25.0%) patients, hepatic steatosis – 3 (25.0%), dismotility – 5 (41.7%) patients. Endocrine damage like dyslipidemia had 4 (33.3%), secondary amenorrhea – 4 (33.3%), diabetes mellitus in 2 (16.6%) patients. Despite moderate disease activity the most common disease outcomes obtained were muscular – 100% patients, gastrointestinal – 91.7% and endocrine – 83.3% patients |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-55552</cfResPublId> <cfResPublDate>2017-07-01</cfResPublDate> <cfVol>73</cfVol> <cfIssue>3</cfIssue> <cfStartPage>143</cfStartPage> <cfISSN>1729-8687</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/55552</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Consecinţele timpurii ale miopatiilor inflamatorii idiopatice</cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p><em>Idiopathic inflammatory myopathies (IIM) are a group of rare diseases characterized by asthenia of skeletal muscles. Early approach to disease leads to a favorable evolution of the disease and less outcomes. The aim of this study is to assess the short-term outcomes in patients with IIM. We conducted a transversal study enrolling 12 patients (7 women, 5 men) with IIM, the mean age was 54.1±12.1 (30–67) years and the follow–up period was 16±9.4, (7-25) months. Patients were assessed by aplying specific questionnaires and modern, validated clinical tools.We found in all patients muscle damage manifested by muscular dysfunction – 11 (91.7%) patients and atrophy in one (8,3%) patient, confirmed by moderate muscle strengh, which implies disability – 10 (83.3%) patients. Gastrointestinal damage was manifested by dysphagia in 3 (25.0%) patients, hepatic steatosis – 3 (25.0%), dismotility – 5 (41.7%) patients. Endocrine damage like dyslipidemia had 4 (33.3%), secondary amenorrhea – 4 (33.3%), diabetes mellitus in 2 (16.6%) patients. Despite moderate disease activity the most common disease outcomes obtained were muscular – 100% patients, gastrointestinal – 91.7% and endocrine – 83.3% patients</em></p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-40018</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-18809</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-27145</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11763</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-40018</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-40018-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Loghin-Oprea</cfFamilyNames> <cfFirstNames>Natalia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-18809</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-18809-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Vetrilă</cfFamilyNames> <cfFirstNames>Snejana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-27145</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-27145-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Mazur-Nicorici</cfFamilyNames> <cfFirstNames>Lucia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11763</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11763-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Mazur</cfFamilyNames> <cfFirstNames>Minodora</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>
|
|
|
